valproic acid has been researched along with Brain Neoplasms in 118 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid (VPA) is an antiepileptic agent with histone deacetylase inhibitor (HDACi) activity shown to sensitize glioblastoma (GBM) cells to radiation in preclinical models." | 9.20 | A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. ( Camphausen, K; Chang, MG; Fine, HA; Holdford, DJ; Krauze, AV; Myrehaug, SD; Shih, J; Smith, S; Tofilon, PJ, 2015) |
| "This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma." | 9.15 | Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. ( Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Forsyth, P; Gorlia, T; Lacombe, D; Macdonald, DR; Mason, W; Mirimanoff, RO; Rossetti, AO; Stupp, R; van den Bent, MJ; Vecht, CJ; Weller, M, 2011) |
| "Valproic acid (VPA) inhibits histone deacetylase and has been reported to induce apoptosis in glioma." | 9.13 | Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. ( Driever, PH; Gnekow, A; Jorch, N; Kortmann, RD; Kramm, C; Pietsch, T; Rutkowski, S; Wolff, JE, 2008) |
| " Valproic acid (VPA), a histone deacetylase inhibitor, is often used as an anti-epileptic drug in patients with brain neoplasms due to its effectiveness and low toxicity profile." | 8.93 | Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence. ( Ii, N; Kawamura, T; Kobayashi, S; Nomoto, Y; Ochiai, S; Sakuma, H; Takada, A; Toyomasu, Y; Watanabe, Y; Yamashita, Y, 2016) |
| "The aim of this study was to investigate the impact of valproic acid (VPA) on survival and prognosis of patients with glioma who underwent postoperative radiotherapy." | 8.12 | Administration of Valproic Acid Improves the Survival of Patients with Glioma Treated with Postoperative Radiotherapy. ( Guan, S; Huang, B; Li, X; Sun, S; Wang, G; Yang, X, 2022) |
| "This study aimed at estimating the cumulative incidence of antiepileptic drug (AED) treatment failure of first-line monotherapy levetiracetam vs valproic acid in glioma patients with epilepsy." | 8.02 | First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid. ( Dirven, L; Fiocco, M; Koekkoek, JAF; Kouwenhoven, MCM; Taphoorn, MJB; van den Bent, MJ; van der Meer, PB; Vos, MJ, 2021) |
| "Valproic acid (VPA), an anticonvulsant and mood-stabilizing drug is used to treat epileptic seizure of glioblastoma patients." | 7.85 | Cellular Effects of the Antiepileptic Drug Valproic Acid in Glioblastoma. ( Eckert, M; Huber, SM; Klumpp, L, 2017) |
| "We studied the potential mechanisms of valproic acid (VPA) in the treatment of glioblastoma multiforme (GBM)." | 7.85 | Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression. ( Chen, CP; Chen, CY; Chen, PC; Fan, CC; Hsiao, SH; Liang, YC; Tseng, JH, 2017) |
| "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)." | 7.83 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. ( Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W, 2016) |
| "The combination of radiotherapy, temozolomide and valproic acid (VPA) has shown some promise in retrospective analyses of patients with glioblastoma, although their mechanisms of action remain unknown." | 7.83 | Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma. ( Bumes, E; Eyüpoglu, IY; Hau, P; Hutterer, M; Proske, J; Savaskan, NE; Seliger, C; Uhl, M; Vollmann-Zwerenz, A; Walter, L, 2016) |
| " 1) VPA treatment clearly sensitized glioma cells to temozolomide: A protruding VPA-induced molecular feature in this context was the transcriptional upregulation/reexpression of numerous solute carrier (SLC) transporters that was also reflected by euchromatinization on the histone level and a reexpression of SLC transporters in human biopsy samples after VPA treatment." | 7.83 | Molecular dissection of the valproic acid effects on glioma cells. ( Hau, P; Herold-Mende, C; Hoja, S; Proescholdt, M; Rehli, M; Riemenschneider, MJ; Schulze, M, 2016) |
| "Valproic acid (VPA), an histone deacetylase inhibitor, is emerging as a promising therapeutic agent for the treatments of gliomas by virtue of its ability to reactivate the expression of epigenetically silenced genes." | 7.80 | Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid. ( Baronchelli, S; Biunno, I; Caldera, V; Cattaneo, M; Daga, A; Dalpra, L; DeBlasio, P; Mellai, M; Orlandi, R; Saccani, GJ; Schiffer, D, 2014) |
| "Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, and it can modulate the biologic effects of radiation therapy (RT)." | 7.79 | Valproic acid use during radiation therapy for glioblastoma associated with improved survival. ( Barker, CA; Beal, K; Bishop, AJ; Chan, TA; Chang, M, 2013) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 7.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| "Temozolomide (TMZ) is given in addition to radiotherapy in glioma patients, but its interaction with the commonly prescribed antiepileptic drug valproic acid (VPA) is largely unknown." | 7.78 | Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. ( Lafleur, MV; Slotman, BJ; Sminia, P; Stalpers, LJ; Van den Berg, J; Van Nifterik, KA, 2012) |
| "The effects of valproic acid (VPA) on the viability, apoptosis, and invasiveness of two glioma cells (A172 and T98G) and the underlying mechanisms were studied." | 7.78 | Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms. ( Chen, Y; Tsai, YH; Tseng, SH, 2012) |
| "Temozolomide (TMZ) has become a key therapeutic agent in patients with malignant gliomas; however, its survival benefit remains unsatisfactory." | 7.78 | Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. ( Hou, Y; Jeong, CH; Jeun, SS; Kim, SM; Lim, JY; Park, KY; Ryu, CH; Woo, JS; Yoon, WS, 2012) |
| "Effects of combinations of the US Food and Drug Administation (FDA) approved proteasome inhibitor bortezomib and the histone deacetylase (HDAC) inhibitors vorinostat, valproic acid and sodium phenylbutyrate were studied on primary glioblastoma stem cell lines and conventional glioblastoma cell lines." | 7.78 | Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors. ( Asklund, T; Bergenheim, T; Hedman, H; Henriksson, R; Holmlund, C; Kvarnbrink, S; Wibom, C, 2012) |
| "An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)." | 7.78 | Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012) |
| " In this study, we investigated the effect of this anticancer drug alone and in combination with a histone deacetylase (HDAC) inhibitor, valproic acid (VPA), on a human UKF-NB-4 neuroblastoma cell line." | 7.78 | Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells. ( Eckschlager, T; Groh, T; Hrabeta, J; Poljakova, J; Stiborova, M, 2012) |
| "The cytotoxicity of ellipticine to neuroblastomas was increased by pre-treating these cells with VPA or TSA." | 7.77 | Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma. ( Dvorakova, M; Eckschlager, T; Frei, E; Göttlicherova, M; Hrabeta, J; Hrebackova, J; Kizek, R; Kopejtkova, B; Moserova, M; Poljakova, J; Stiborova, M, 2011) |
| "C6 glioma cells were treated with clinically relevant concentrations of valproic acid (0." | 7.74 | Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells. ( Jawed, S; Kim, B; Niles, LP; Rincón Castro, LM, 2008) |
| "Glioblastoma patients undergoing treatment with surgery followed by radiation and temozolomide chemotherapy often develop a state of immunosuppression and are at risk for opportunistic infections and reactivation of hepatitis and herpes viruses." | 7.74 | Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. ( Hoorens, A; Neyns, B; Stupp, R, 2008) |
| " In this study, we have examined the ability of the histone deacetylase inhibitor, valproic acid (VPA) to modulate gene expression and sensitize glioblastoma cell lines to the cytotoxic effects of etoposide in vitro." | 7.74 | Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. ( Aguilera, D; Das, CM; Gopalakrishnan, V; Prasad, P; Vasquez, H; Wolff, JE; Zhang, M, 2007) |
| "Inositol uptake was measured at concentrations of 25, 40 and 50 microM in human astrocytoma cell cultures treated for 1-3 weeks with pharmacologically relevant concentrations of LiCl, valproic acid or carbamazepine as well as in control cultures that had not been treated with any drug." | 7.70 | Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations. ( Belmaker, RH; Bersudsky, Y; Hertz, L; Simkin, M; Wolfson, M; Zinger, E, 2000) |
| "Glioma is the most common primary malignant brain tumor in adults and the patients have poor prognosis despite treatment with surgery, radiotherapy and chemotherapy." | 6.66 | The therapeutic and neuroprotective effects of an antiepileptic drug valproic acid in glioma patients. ( Chen, H; Li, C; Sharma, A; Sharma, HS; Tan, Q; Xie, C; Zhan, W; Zhang, Z, 2020) |
| "Glioblastoma multiforme is the most common and aggressive primary brain tumor." | 6.48 | Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results. ( Berendsen, S; Broekman, M; de Vos, F; Regli, L; Robe, P; Seute, T; Snijders, T; van Es, C, 2012) |
| "Luteolin has been detected to exert limited anti-tumor effects on gliomas, while valproic acid (VPA) is a common chemotherapy sensitizer in the treatment of tumors." | 5.62 | Valproic Acid Sensitizes Glioma Cells to Luteolin Through Induction of Apoptosis and Autophagy via Akt Signaling. ( Guan, W; Han, W; Wang, R; Yu, F; Zhi, F, 2021) |
| "Epileptic seizures are frequent in patients with glioblastoma, and anticonvulsive treatment is often necessary." | 5.51 | AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro. ( Bergner, C; Hörnschemeyer, J; Kirschstein, T; Köhling, R; Krause, BJ; Lange, F; Linnebacher, M; Mullins, CS; Porath, K; Weßlau, K, 2019) |
| "Valproic acid (VPA) is an anti-epileptic drug with properties of a histone deacetylase inhibitor (HDACi)." | 5.43 | Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. ( Dietrich, J; Le, A; McDonnell, E; Nahed, BV; Redjal, N; Reinshagen, C; Walcott, BP, 2016) |
| " Haematological toxicity is a limiting side effect of both, first line radio-chemotherapy with temozolomide (TMZ) and co-medication with antiepileptic drugs." | 5.42 | Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. ( Geroldinger, A; Gleiss, A; Grisold, W; Marosi, C; Moser, W; Oberndorfer, S; Sax, C; Sherif, C; Tinchon, A, 2015) |
| " Primary GBM cells were treated with VPA as a monotherapy and in combination with temozolomide and irradiation." | 5.42 | The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. ( Cosgrove, L; Day, B; Fay, M; Head, R; Hosein, AN; Lim, YC; Martin, JH; Rose, S; Sminia, P; Stringer, B, 2015) |
| "Valproic acid (VPA) treatment protected hippocampal neurons from radiation-induced damage in both cell culture and animal models." | 5.42 | Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells. ( DeWees, TA; Engelbach, JA; Garbow, JR; Hallahan, AN; Hallahan, DE; Karvas, RM; Laszlo, A; Thotala, D, 2015) |
| "This retrospective study compared the seizure outcomes, side effects and durability of levetiracetam with valproic acid after a craniotomy for supratentorial brain tumors." | 5.39 | Levetiracetam compared with valproic acid for the prevention of postoperative seizures after supratentorial tumor surgery: a retrospective chart review. ( Bae, SH; Han, JH; Kim, CY; Kim, T; Kim, YH; Lee, YJ; Yun, CH, 2013) |
| "Valproic acid (VPA) is a potential anticancer agent that belongs to a class of histone deacetylase (HDAC) inhibitors, targeting the epigenetic control of gene functions in cancer cells." | 5.38 | Effect of valproic acid on the outcome of glioblastoma multiforme. ( Chen, PY; Chen, SM; Huang, YC; Lee, ST; Lu, YJ; Tsai, CN; Tsai, HC; Wei, KC, 2012) |
| "Valproic acid (VPA) has been shown to induce growth-arrest and differentiation of human neuroectodermal tumors similarly to several other fatty acids." | 5.31 | Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. ( Blaheta, R; Cinatl, J; Driever, PH; Kotchetkov, R; Vogel, JU, 2002) |
| "Valproic acid (VPA) is an anticonvulsant drug with demonstrated efficacy in the treatment of mania." | 5.29 | Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. ( Chen, G; Hawver, DB; Manji, HK; Potter, WZ; Wright, CB, 1996) |
| " Potential add-on AEDs in case of uncontrolled seizures include lacosamide, perampanel, and valproic acid." | 5.22 | Management of epilepsy in brain tumor patients. ( Koekkoek, JAF; Taphoorn, MJB; van der Meer, PB, 2022) |
| "Valproic acid (VPA) is an antiepileptic agent with histone deacetylase inhibitor (HDACi) activity shown to sensitize glioblastoma (GBM) cells to radiation in preclinical models." | 5.20 | A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. ( Camphausen, K; Chang, MG; Fine, HA; Holdford, DJ; Krauze, AV; Myrehaug, SD; Shih, J; Smith, S; Tofilon, PJ, 2015) |
| "This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma." | 5.15 | Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. ( Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Forsyth, P; Gorlia, T; Lacombe, D; Macdonald, DR; Mason, W; Mirimanoff, RO; Rossetti, AO; Stupp, R; van den Bent, MJ; Vecht, CJ; Weller, M, 2011) |
| "Valproic acid (VPA) inhibits histone deacetylase and has been reported to induce apoptosis in glioma." | 5.13 | Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. ( Driever, PH; Gnekow, A; Jorch, N; Kortmann, RD; Kramm, C; Pietsch, T; Rutkowski, S; Wolff, JE, 2008) |
| " Valproic acid (VPA), a histone deacetylase inhibitor, is often used as an anti-epileptic drug in patients with brain neoplasms due to its effectiveness and low toxicity profile." | 4.93 | Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence. ( Ii, N; Kawamura, T; Kobayashi, S; Nomoto, Y; Ochiai, S; Sakuma, H; Takada, A; Toyomasu, Y; Watanabe, Y; Yamashita, Y, 2016) |
| "No evidence supports AED prophylaxis with phenobarbital, phenytoin, or valproic acid in patients with brain tumors and no history of seizures, regardless of neoplastic type." | 4.82 | Seizure prophylaxis in patients with brain tumors: a meta-analysis. ( Drazkowski, JF; Lyons, MK; Sirven, JI; Wingerchuk, DM; Zimmerman, RS, 2004) |
| "The aim of this study was to investigate the impact of valproic acid (VPA) on survival and prognosis of patients with glioma who underwent postoperative radiotherapy." | 4.12 | Administration of Valproic Acid Improves the Survival of Patients with Glioma Treated with Postoperative Radiotherapy. ( Guan, S; Huang, B; Li, X; Sun, S; Wang, G; Yang, X, 2022) |
| "This study aimed at estimating the cumulative incidence of antiepileptic drug (AED) treatment failure of first-line monotherapy levetiracetam vs valproic acid in glioma patients with epilepsy." | 4.02 | First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid. ( Dirven, L; Fiocco, M; Koekkoek, JAF; Kouwenhoven, MCM; Taphoorn, MJB; van den Bent, MJ; van der Meer, PB; Vos, MJ, 2021) |
| " The impact of the chemotherapeutic temozolomide (TMZ) in combination with valproic acid (VPA) was tested in two pediatric glioblastoma-derived cell lines." | 3.96 | Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro. ( Gielen, G; Hüttelmaier, S; Klusmann, JH; Kramm, C; Kühnöl, CD; Pietsch, T; Pötschke, R, 2020) |
| "Valproic acid (VPA), an anticonvulsant and mood-stabilizing drug is used to treat epileptic seizure of glioblastoma patients." | 3.85 | Cellular Effects of the Antiepileptic Drug Valproic Acid in Glioblastoma. ( Eckert, M; Huber, SM; Klumpp, L, 2017) |
| "We studied the potential mechanisms of valproic acid (VPA) in the treatment of glioblastoma multiforme (GBM)." | 3.85 | Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression. ( Chen, CP; Chen, CY; Chen, PC; Fan, CC; Hsiao, SH; Liang, YC; Tseng, JH, 2017) |
| "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)." | 3.83 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. ( Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W, 2016) |
| "The combination of radiotherapy, temozolomide and valproic acid (VPA) has shown some promise in retrospective analyses of patients with glioblastoma, although their mechanisms of action remain unknown." | 3.83 | Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma. ( Bumes, E; Eyüpoglu, IY; Hau, P; Hutterer, M; Proske, J; Savaskan, NE; Seliger, C; Uhl, M; Vollmann-Zwerenz, A; Walter, L, 2016) |
| " 1) VPA treatment clearly sensitized glioma cells to temozolomide: A protruding VPA-induced molecular feature in this context was the transcriptional upregulation/reexpression of numerous solute carrier (SLC) transporters that was also reflected by euchromatinization on the histone level and a reexpression of SLC transporters in human biopsy samples after VPA treatment." | 3.83 | Molecular dissection of the valproic acid effects on glioma cells. ( Hau, P; Herold-Mende, C; Hoja, S; Proescholdt, M; Rehli, M; Riemenschneider, MJ; Schulze, M, 2016) |
| "We report the case of an aborted awake craniotomy for a left frontotemporoinsular glioma due to ammonia encephalopathy on a patient taking Levetiracetam, valproic acid and clobazam." | 3.81 | Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy. ( Arroyo Pérez, R; Fernández-Candil, JL; León Jorba, A; Pacreu Terradas, S; Villalba Martínez, G; Vivanco-Hidalgo, RM, 2015) |
| "Valproic acid (VPA), an histone deacetylase inhibitor, is emerging as a promising therapeutic agent for the treatments of gliomas by virtue of its ability to reactivate the expression of epigenetically silenced genes." | 3.80 | Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid. ( Baronchelli, S; Biunno, I; Caldera, V; Cattaneo, M; Daga, A; Dalpra, L; DeBlasio, P; Mellai, M; Orlandi, R; Saccani, GJ; Schiffer, D, 2014) |
| "We report the cases of 2 breast cancer patients who received capecitabine(CAP)and concomitant anticonvulsant therapy with either phenytoin(PHT)or valproate(VPA)for brain metastasis." | 3.80 | [Effect of capecitabine therapy on the blood levels of antiepileptic drugs - report of two cases]. ( Ibayashi, Y; Jotoku, H; Takahashi, M; Takasaki, M; Tanaka, H; Watanabe, K, 2014) |
| "We found that VPA and TSA increase histone H4 acetylation in glioma cells, while chaetocin and BIX01294 at low concentrations reduce H3K9me3, and 3DZNep decreases H3K27me3." | 3.80 | The effects of selected inhibitors of histone modifying enzyme on C6 glioma cells. ( Kaminska, B; Maleszewska, M; Steranka, A, 2014) |
| "Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, and it can modulate the biologic effects of radiation therapy (RT)." | 3.79 | Valproic acid use during radiation therapy for glioblastoma associated with improved survival. ( Barker, CA; Beal, K; Bishop, AJ; Chan, TA; Chang, M, 2013) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 3.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| "Temozolomide (TMZ) is given in addition to radiotherapy in glioma patients, but its interaction with the commonly prescribed antiepileptic drug valproic acid (VPA) is largely unknown." | 3.78 | Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. ( Lafleur, MV; Slotman, BJ; Sminia, P; Stalpers, LJ; Van den Berg, J; Van Nifterik, KA, 2012) |
| "The effects of valproic acid (VPA) on the viability, apoptosis, and invasiveness of two glioma cells (A172 and T98G) and the underlying mechanisms were studied." | 3.78 | Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms. ( Chen, Y; Tsai, YH; Tseng, SH, 2012) |
| "Temozolomide (TMZ) has become a key therapeutic agent in patients with malignant gliomas; however, its survival benefit remains unsatisfactory." | 3.78 | Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. ( Hou, Y; Jeong, CH; Jeun, SS; Kim, SM; Lim, JY; Park, KY; Ryu, CH; Woo, JS; Yoon, WS, 2012) |
| "Effects of combinations of the US Food and Drug Administation (FDA) approved proteasome inhibitor bortezomib and the histone deacetylase (HDAC) inhibitors vorinostat, valproic acid and sodium phenylbutyrate were studied on primary glioblastoma stem cell lines and conventional glioblastoma cell lines." | 3.78 | Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors. ( Asklund, T; Bergenheim, T; Hedman, H; Henriksson, R; Holmlund, C; Kvarnbrink, S; Wibom, C, 2012) |
| "An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)." | 3.78 | Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012) |
| " In this study, we investigated the effect of this anticancer drug alone and in combination with a histone deacetylase (HDAC) inhibitor, valproic acid (VPA), on a human UKF-NB-4 neuroblastoma cell line." | 3.78 | Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells. ( Eckschlager, T; Groh, T; Hrabeta, J; Poljakova, J; Stiborova, M, 2012) |
| "The cytotoxicity of ellipticine to neuroblastomas was increased by pre-treating these cells with VPA or TSA." | 3.77 | Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma. ( Dvorakova, M; Eckschlager, T; Frei, E; Göttlicherova, M; Hrabeta, J; Hrebackova, J; Kizek, R; Kopejtkova, B; Moserova, M; Poljakova, J; Stiborova, M, 2011) |
| "C6 glioma cells were treated with clinically relevant concentrations of valproic acid (0." | 3.74 | Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells. ( Jawed, S; Kim, B; Niles, LP; Rincón Castro, LM, 2008) |
| "The effects of the HDAC inhibitor valproic acid (VA) on postirradiation sensitivity in human glioma cell lines were evaluated using a clonogenic assay, exposing cells to VA up to 24 h after irradiation." | 3.74 | Postradiation sensitization of the histone deacetylase inhibitor valproic acid. ( Beam, K; Burgan, WE; Camphausen, K; Cerna, D; Chinnaiyan, P; Tofilon, PJ; Williams, ES, 2008) |
| "Glioblastoma patients undergoing treatment with surgery followed by radiation and temozolomide chemotherapy often develop a state of immunosuppression and are at risk for opportunistic infections and reactivation of hepatitis and herpes viruses." | 3.74 | Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. ( Hoorens, A; Neyns, B; Stupp, R, 2008) |
| " The authors evaluated the cytotoxicity of histone deacetylase inhibitors (HDI) [MS-275, SAHA, TSA, M344, M360, D85, SW55, SW187 and valproic acid (VPA)] on 13 embryonal tumor cell lines [4 medulloblastomas, 5 neuroblastomas, 2 atypical teratoid/rhabdoid tumors (AT/RT), and 2 malignant rhabdoid tumors of the kidney (RTK)] in MTT assay." | 3.74 | Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. ( Frühwald, MC; Furchert, SE; Jung, M; Juürgens, H; Lanvers-Kaminsky, C; Loidl, A, 2007) |
| " In this study, we have examined the ability of the histone deacetylase inhibitor, valproic acid (VPA) to modulate gene expression and sensitize glioblastoma cell lines to the cytotoxic effects of etoposide in vitro." | 3.74 | Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. ( Aguilera, D; Das, CM; Gopalakrishnan, V; Prasad, P; Vasquez, H; Wolff, JE; Zhang, M, 2007) |
| " Patients with high-grade gliomas were treated with up-front chemotherapy regimen consisting of fotemustine (d3: 100 mg/m2), cisplatin (d1-3: 33 mg/m2) and etoposide (d1-3: 75 mg/m2) followed by whole brain radiotherapy at progression." | 3.71 | Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. ( Bourg, V; Chichmanian, RM; Frenay, M; Lebrun, C; Thomas, P, 2001) |
| "Inositol uptake was measured at concentrations of 25, 40 and 50 microM in human astrocytoma cell cultures treated for 1-3 weeks with pharmacologically relevant concentrations of LiCl, valproic acid or carbamazepine as well as in control cultures that had not been treated with any drug." | 3.70 | Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations. ( Belmaker, RH; Bersudsky, Y; Hertz, L; Simkin, M; Wolfson, M; Zinger, E, 2000) |
| "Epilepsy is the most common symptom in patients with brain tumors." | 3.01 | Epilepsy and brain tumors: Two sides of the same coin. ( Aronica, E; Ciusani, E; Coppola, A; Costa, C; Maschio, M; Perversi, F; Russo, E; Salmaggi, A, 2023) |
| " Careful selection of appropriate in vitro and in vivo models to demonstrate increased radiosensitivity and suitable bioavailability are then necessary to prove that a drug warrants advancement to clinical investigation." | 2.72 | Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma. ( Camphausen, K; Degorre, C; Mathen, P; Tofilon, P, 2021) |
| "In patients with newly diagnosed brain tumors who have not had a seizure, clinicians should not prescribe antiepileptic drugs (AEDs) to reduce the risk of seizures (level A)." | 2.72 | SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. ( Avila, EK; Chen, M; Gerstner, ER; Harrison, RA; Kandula, P; Le Rhun, E; Lee, JW; Schiff, D; Stevens, GHJ; Vogelbaum, MA; Walbert, T; Weller, M; Wen, PY; Wick, W, 2021) |
| " Compliance and adequacy of dosing were assessed by pill counts and monthly blood levels." | 2.68 | A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. ( Akerley, W; Choy, H; Cole, BF; Friedberg, MH; Furie, K; Glantz, MJ; Lathi, E; Lekos, A; Louis, S; Wahlberg, L, 1996) |
| "Glioma is the most common primary malignant brain tumor in adults and the patients have poor prognosis despite treatment with surgery, radiotherapy and chemotherapy." | 2.66 | The therapeutic and neuroprotective effects of an antiepileptic drug valproic acid in glioma patients. ( Chen, H; Li, C; Sharma, A; Sharma, HS; Tan, Q; Xie, C; Zhan, W; Zhang, Z, 2020) |
| "The use of AEDs for purposes other than seizure prophylaxis and their selection based on non-PK properties present a potential paradigm shift in the field of neuro-oncology." | 2.53 | Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics. ( Gefroh-Grimes, HA; Gidal, BE, 2016) |
| "Glioblastoma multiforme is the most common and aggressive primary brain tumor." | 2.48 | Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results. ( Berendsen, S; Broekman, M; de Vos, F; Regli, L; Robe, P; Seute, T; Snijders, T; van Es, C, 2012) |
| "Glioblastoma multiforme is the most common malignant primary brain tumor in adults." | 1.72 | Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines. ( Doello, K; Mesas, C; Ortiz, R; Perazzoli, G; Quiñonero, F; Rama, AR; Vélez, C, 2022) |
| "Luteolin has been detected to exert limited anti-tumor effects on gliomas, while valproic acid (VPA) is a common chemotherapy sensitizer in the treatment of tumors." | 1.62 | Valproic Acid Sensitizes Glioma Cells to Luteolin Through Induction of Apoptosis and Autophagy via Akt Signaling. ( Guan, W; Han, W; Wang, R; Yu, F; Zhi, F, 2021) |
| "Epileptic seizures are frequent in patients with glioblastoma, and anticonvulsive treatment is often necessary." | 1.51 | AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro. ( Bergner, C; Hörnschemeyer, J; Kirschstein, T; Köhling, R; Krause, BJ; Lange, F; Linnebacher, M; Mullins, CS; Porath, K; Weßlau, K, 2019) |
| "Epilepsy is an independent prognostic factor for longer survival in glioblastoma patients." | 1.43 | Prognostic relevance of epilepsy at presentation in glioblastoma patients. ( Berendsen, S; Bours, V; Broekman, ML; Kauw, F; Kroonen, J; Poulet, C; Robe, PA; Seute, T; Snijders, TJ; Spliet, WG; Varkila, M; Willems, M, 2016) |
| "Valproic acid (VPA) is an anti-epileptic drug with properties of a histone deacetylase inhibitor (HDACi)." | 1.43 | Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. ( Dietrich, J; Le, A; McDonnell, E; Nahed, BV; Redjal, N; Reinshagen, C; Walcott, BP, 2016) |
| " Haematological toxicity is a limiting side effect of both, first line radio-chemotherapy with temozolomide (TMZ) and co-medication with antiepileptic drugs." | 1.42 | Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. ( Geroldinger, A; Gleiss, A; Grisold, W; Marosi, C; Moser, W; Oberndorfer, S; Sax, C; Sherif, C; Tinchon, A, 2015) |
| " Primary GBM cells were treated with VPA as a monotherapy and in combination with temozolomide and irradiation." | 1.42 | The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. ( Cosgrove, L; Day, B; Fay, M; Head, R; Hosein, AN; Lim, YC; Martin, JH; Rose, S; Sminia, P; Stringer, B, 2015) |
| "Valproic acid (VPA) treatment protected hippocampal neurons from radiation-induced damage in both cell culture and animal models." | 1.42 | Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells. ( DeWees, TA; Engelbach, JA; Garbow, JR; Hallahan, AN; Hallahan, DE; Karvas, RM; Laszlo, A; Thotala, D, 2015) |
| " The symptoms of VHE were not correlated with the dosage and concentration of valproate." | 1.40 | [Clinical misdiagnosis analysis of valproate encephalopathy]. ( Chen, X; Su, Z; Wu, Z; Ye, S; Zhu, D; Zhuge, G, 2014) |
| "This retrospective study compared the seizure outcomes, side effects and durability of levetiracetam with valproic acid after a craniotomy for supratentorial brain tumors." | 1.39 | Levetiracetam compared with valproic acid for the prevention of postoperative seizures after supratentorial tumor surgery: a retrospective chart review. ( Bae, SH; Han, JH; Kim, CY; Kim, T; Kim, YH; Lee, YJ; Yun, CH, 2013) |
| "A currently studied experimental treatment for gliomas consists of intratumoral injection of oncolytic viruses (OV), such as oncolytic herpes simplex virus type 1 (oHSV)." | 1.39 | STAT3 activation promotes oncolytic HSV1 replication in glioma cells. ( Chiocca, EA; Haseley, A; Kaur, B; Meisen, H; Okemoto, K; Wagner, B, 2013) |
| "In vivo, pre-treatment of AR breast tumors in the brain with valproate restored the chemo-sensitivity of the tumors and prolonged animal survival." | 1.39 | Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. ( Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S, 2013) |
| "Valproic acid (VPA) is a potential anticancer agent that belongs to a class of histone deacetylase (HDAC) inhibitors, targeting the epigenetic control of gene functions in cancer cells." | 1.38 | Effect of valproic acid on the outcome of glioblastoma multiforme. ( Chen, PY; Chen, SM; Huang, YC; Lee, ST; Lu, YJ; Tsai, CN; Tsai, HC; Wei, KC, 2012) |
| "Valproic acid (VPA) is an established drug in the long-term therapy of epilepsy." | 1.36 | Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells. ( Ferreri, AM; Guerra, F; Orlandi, M; Papi, A; Rocchi, P, 2010) |
| "Eating-induced seizures are an uncommon presentation of reflex epilepsy, a condition characterized by seizures provoked by specific stimuli." | 1.36 | Unilateral opercular lesion and eating-induced seizures. ( Friedman, DE; Kung, DH; Manyam, SC; Newmark, ME; Rhodes, LB, 2010) |
| "Although seizures in brain tumor patients are common, the knowledge on optimal anti-seizure therapy in this patient group is limited." | 1.35 | Efficacy of anti-epileptic drugs in patients with gliomas and seizures. ( Rijsman, RM; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2009) |
| "Valproic acid (VA) is a well-tolerated drug used to treat seizure disorders and has recently been shown to inhibit histone deacetylase (HDAC)." | 1.33 | Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. ( Burgan, WE; Camphausen, K; Cerna, D; Cerra, MA; Fine, H; Scott, T; Sproull, M; Tofilon, PJ, 2005) |
| "The case of a 12-year-old boy with anaplastic astrocytoma of the left thalamus is reported." | 1.33 | Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid. ( Csatary, CM; Csatary, LK; Gosztonyi, G; Hartmann, C; Hernáiz-Driever, P; Koch, HC; Längler, A; Peters, O; Théallier-Janko, A; Wagner, S; Wolff, JE; Zintl, F, 2006) |
| "Right hemispheric brain tumors involving the orbitofrontal or basotemporal cortex are a rare cause of secondary mania." | 1.32 | Exacerbation of mania secondary to right temporal lobe astrocytoma in a bipolar patient previously stabilized on valproate. ( Denson, TF; Sokolski, KN, 2003) |
| "Valproic acid (VPA) has been shown to induce growth-arrest and differentiation of human neuroectodermal tumors similarly to several other fatty acids." | 1.31 | Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. ( Blaheta, R; Cinatl, J; Driever, PH; Kotchetkov, R; Vogel, JU, 2002) |
| " In addition, there was a significant dose-response association between the development of procarbazine hypersensitivity and the presence of therapeutic anticonvulsant serum levels (p = 0." | 1.30 | Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. ( Coyle, TE; Hurteau, TE; Lehmann, DF; Newman, N, 1997) |
| " All these patients were receiving the usual dosage (1000 to 1500 mg per day) of Valproic acid (VPA)." | 1.29 | Impairment of consciousness induced by valproate treatment following neurosurgical operation. ( Baulac, M; de Billy, A; Durand, G; Landau, J; Philippon, J, 1993) |
| "Valproic acid (VPA) is an anticonvulsant drug with demonstrated efficacy in the treatment of mania." | 1.29 | Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. ( Chen, G; Hawver, DB; Manji, HK; Potter, WZ; Wright, CB, 1996) |
| "Cerebral cavernous angioma (cavernoma) has previously been treated by resection for all presentations when surgically resectable." | 1.28 | Cerebral cavernous angioma: a potentially benign condition? Successful treatment in 16 cases. ( Churchyard, A; Grainger, K; Khangure, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (6.78) | 18.2507 |
| 2000's | 22 (18.64) | 29.6817 |
| 2010's | 72 (61.02) | 24.3611 |
| 2020's | 16 (13.56) | 2.80 |
| Authors | Studies |
|---|---|
| Degorre, C | 1 |
| Tofilon, P | 1 |
| Camphausen, K | 4 |
| Mathen, P | 1 |
| Yang, ZY | 1 |
| Wang, XH | 1 |
| van der Meer, PB | 2 |
| Taphoorn, MJB | 2 |
| Koekkoek, JAF | 2 |
| Wang, G | 1 |
| Guan, S | 1 |
| Yang, X | 1 |
| Sun, S | 1 |
| Huang, B | 1 |
| Li, X | 1 |
| Doello, K | 3 |
| Mesas, C | 3 |
| Quiñonero, F | 3 |
| Rama, AR | 3 |
| Vélez, C | 3 |
| Perazzoli, G | 3 |
| Ortiz, R | 3 |
| Aronica, E | 1 |
| Ciusani, E | 1 |
| Coppola, A | 1 |
| Costa, C | 1 |
| Russo, E | 1 |
| Salmaggi, A | 2 |
| Perversi, F | 1 |
| Maschio, M | 2 |
| Natale, G | 1 |
| Fini, E | 1 |
| Calabrò, PF | 1 |
| Carli, M | 1 |
| Scarselli, M | 1 |
| Bocci, G | 1 |
| Pötschke, R | 1 |
| Gielen, G | 1 |
| Pietsch, T | 2 |
| Kramm, C | 2 |
| Klusmann, JH | 1 |
| Hüttelmaier, S | 1 |
| Kühnöl, CD | 1 |
| Tan, TSE | 1 |
| Sanamandra, SK | 1 |
| Kuo, YJ | 1 |
| Yang, YH | 1 |
| Lee, IY | 1 |
| Chen, PC | 2 |
| Yang, JT | 2 |
| Wang, TC | 1 |
| Lin, MH | 2 |
| Yang, WH | 1 |
| Cheng, CY | 1 |
| Chen, KT | 1 |
| Huang, WC | 1 |
| Lee, MH | 2 |
| Han, W | 1 |
| Yu, F | 1 |
| Wang, R | 2 |
| Guan, W | 1 |
| Zhi, F | 1 |
| Li, C | 1 |
| Chen, H | 1 |
| Tan, Q | 1 |
| Xie, C | 1 |
| Zhan, W | 1 |
| Sharma, A | 1 |
| Sharma, HS | 1 |
| Zhang, Z | 1 |
| Park, SA | 1 |
| Han, HR | 1 |
| Ahn, S | 1 |
| Ryu, CH | 3 |
| Jeun, SS | 3 |
| Dirven, L | 1 |
| Fiocco, M | 1 |
| Vos, MJ | 1 |
| Kouwenhoven, MCM | 1 |
| van den Bent, MJ | 2 |
| Walbert, T | 1 |
| Harrison, RA | 1 |
| Schiff, D | 2 |
| Avila, EK | 1 |
| Chen, M | 1 |
| Kandula, P | 1 |
| Lee, JW | 1 |
| Le Rhun, E | 1 |
| Stevens, GHJ | 1 |
| Vogelbaum, MA | 1 |
| Wick, W | 2 |
| Weller, M | 4 |
| Wen, PY | 2 |
| Gerstner, ER | 1 |
| Kresbach, C | 1 |
| Bronsema, A | 1 |
| Guerreiro, H | 1 |
| Rutkowski, S | 2 |
| Schüller, U | 1 |
| Winkler, B | 1 |
| Tountopoulou, M | 1 |
| Weschke, B | 1 |
| Kaindl, AM | 1 |
| O'Connor, N | 1 |
| Hayden, C | 1 |
| O'Leary, N | 1 |
| Raja, E | 1 |
| Komuro, A | 1 |
| Tanabe, R | 1 |
| Sakai, S | 1 |
| Ino, Y | 1 |
| Saito, N | 1 |
| Todo, T | 1 |
| Morikawa, M | 1 |
| Aburatani, H | 1 |
| Koinuma, D | 1 |
| Iwata, C | 1 |
| Miyazono, K | 1 |
| Tarasenko, N | 1 |
| Chekroun-Setti, H | 1 |
| Nudelman, A | 1 |
| Rephaeli, A | 1 |
| Eckert, M | 1 |
| Klumpp, L | 1 |
| Huber, SM | 1 |
| Garcia, CG | 1 |
| Kahn, SA | 1 |
| Geraldo, LHM | 1 |
| Romano, I | 1 |
| Domith, I | 1 |
| Silva, DCLE | 1 |
| Dos Santos Assunção, F | 1 |
| Ferreira, MJ | 1 |
| Portugal, CC | 1 |
| de Souza, JM | 1 |
| Romão, LF | 1 |
| Netto, ADP | 1 |
| Lima, FRS | 1 |
| Cossenza, M | 1 |
| Ishiguro, Y | 1 |
| Kobayashi, M | 1 |
| Ideno, M | 1 |
| Narumi, K | 1 |
| Furugen, A | 1 |
| Iseki, K | 1 |
| Lu, VM | 1 |
| Texakalidis, P | 1 |
| McDonald, KL | 1 |
| Mekary, RA | 1 |
| Smith, TR | 1 |
| Lange, F | 1 |
| Weßlau, K | 1 |
| Porath, K | 1 |
| Hörnschemeyer, J | 1 |
| Bergner, C | 1 |
| Krause, BJ | 1 |
| Mullins, CS | 1 |
| Linnebacher, M | 1 |
| Köhling, R | 1 |
| Kirschstein, T | 1 |
| Laghari, AA | 1 |
| Ahmed, SI | 1 |
| Qadeer, N | 1 |
| Shamim, MS | 1 |
| Luo, D | 1 |
| Fraga-Lauhirat, M | 1 |
| Millings, J | 1 |
| Ho, C | 1 |
| Villarreal, EM | 1 |
| Fletchinger, TC | 1 |
| Bonfiglio, JV | 1 |
| Mata, L | 1 |
| Nemesure, MD | 1 |
| Bartels, LE | 1 |
| Rigas, B | 1 |
| Mackenzie, GG | 1 |
| Chen, JC | 1 |
| Lee, IN | 1 |
| Huang, C | 1 |
| Wu, YP | 1 |
| Chung, CY | 1 |
| Guthrie, G | 1 |
| Eljamel, S | 2 |
| Barker, CA | 1 |
| Bishop, AJ | 1 |
| Chang, M | 1 |
| Beal, K | 1 |
| Chan, TA | 1 |
| Kapoor, S | 1 |
| Kerkhof, M | 1 |
| Dielemans, JC | 1 |
| van Breemen, MS | 2 |
| Zwinkels, H | 2 |
| Walchenbach, R | 2 |
| Taphoorn, MJ | 2 |
| Vecht, CJ | 3 |
| Lee, YJ | 1 |
| Kim, T | 1 |
| Bae, SH | 1 |
| Kim, YH | 1 |
| Han, JH | 1 |
| Yun, CH | 1 |
| Kim, CY | 1 |
| Okemoto, K | 2 |
| Wagner, B | 1 |
| Meisen, H | 1 |
| Haseley, A | 1 |
| Kaur, B | 1 |
| Chiocca, EA | 3 |
| Cruickshanks, N | 1 |
| Hamed, HA | 1 |
| Booth, L | 1 |
| Tavallai, S | 1 |
| Syed, J | 1 |
| Sajithlal, GB | 1 |
| Grant, S | 1 |
| Poklepovic, A | 1 |
| Dent, P | 1 |
| Rigamonti, A | 1 |
| Lauria, G | 1 |
| Grimod, G | 1 |
| Bianchi, G | 1 |
| Cattaneo, M | 2 |
| Baronchelli, S | 1 |
| Schiffer, D | 2 |
| Mellai, M | 2 |
| Caldera, V | 1 |
| Saccani, GJ | 1 |
| Dalpra, L | 1 |
| Daga, A | 1 |
| Orlandi, R | 1 |
| DeBlasio, P | 1 |
| Biunno, I | 2 |
| Rubner, Y | 1 |
| Muth, C | 1 |
| Strnad, A | 1 |
| Derer, A | 1 |
| Sieber, R | 1 |
| Buslei, R | 1 |
| Frey, B | 1 |
| Fietkau, R | 1 |
| Gaipl, US | 1 |
| Tanaka, H | 1 |
| Jotoku, H | 1 |
| Takasaki, M | 1 |
| Ibayashi, Y | 1 |
| Watanabe, K | 1 |
| Takahashi, M | 1 |
| Bezecny, P | 1 |
| Maleszewska, M | 1 |
| Steranka, A | 1 |
| Kaminska, B | 1 |
| Yuan, Y | 1 |
| Xiang, W | 1 |
| Qing, M | 1 |
| Yanhui, L | 1 |
| Jiewen, L | 1 |
| Yunhe, M | 1 |
| Tinchon, A | 1 |
| Oberndorfer, S | 1 |
| Marosi, C | 1 |
| Gleiss, A | 1 |
| Geroldinger, A | 1 |
| Sax, C | 1 |
| Sherif, C | 1 |
| Moser, W | 1 |
| Grisold, W | 1 |
| Villalba Martínez, G | 1 |
| Fernández-Candil, JL | 1 |
| Vivanco-Hidalgo, RM | 1 |
| Pacreu Terradas, S | 1 |
| León Jorba, A | 1 |
| Arroyo Pérez, R | 1 |
| Zhu, D | 1 |
| Su, Z | 1 |
| Ye, S | 1 |
| Chen, X | 1 |
| Zhuge, G | 1 |
| Wu, Z | 1 |
| Hosein, AN | 1 |
| Lim, YC | 1 |
| Day, B | 1 |
| Stringer, B | 1 |
| Rose, S | 1 |
| Head, R | 2 |
| Cosgrove, L | 2 |
| Sminia, P | 3 |
| Fay, M | 1 |
| Martin, JH | 2 |
| Storaci, AM | 1 |
| Annovazzi, L | 1 |
| Cassoni, P | 1 |
| Melcarne, A | 1 |
| De Blasio, P | 1 |
| Gefroh-Grimes, HA | 1 |
| Gidal, BE | 1 |
| Krauze, AV | 1 |
| Myrehaug, SD | 1 |
| Chang, MG | 1 |
| Holdford, DJ | 1 |
| Smith, S | 1 |
| Shih, J | 1 |
| Tofilon, PJ | 3 |
| Fine, HA | 1 |
| Thotala, D | 1 |
| Karvas, RM | 1 |
| Engelbach, JA | 1 |
| Garbow, JR | 1 |
| Hallahan, AN | 1 |
| DeWees, TA | 1 |
| Laszlo, A | 1 |
| Hallahan, DE | 1 |
| Berendsen, S | 2 |
| Varkila, M | 1 |
| Kroonen, J | 1 |
| Seute, T | 2 |
| Snijders, TJ | 1 |
| Kauw, F | 1 |
| Spliet, WG | 1 |
| Willems, M | 1 |
| Poulet, C | 1 |
| Broekman, ML | 1 |
| Bours, V | 1 |
| Robe, PA | 1 |
| Nakashima, H | 1 |
| Kaufmann, JK | 1 |
| Wang, PY | 1 |
| Nguyen, T | 1 |
| Speranza, MC | 1 |
| Kasai, K | 2 |
| Otsuki, A | 2 |
| Nakano, I | 1 |
| Fernandez, S | 1 |
| Goins, WF | 1 |
| Grandi, P | 1 |
| Glorioso, JC | 1 |
| Lawler, S | 1 |
| Cripe, TP | 1 |
| Happold, C | 1 |
| Gorlia, T | 2 |
| Chinot, O | 1 |
| Gilbert, MR | 1 |
| Nabors, LB | 1 |
| Pugh, SL | 1 |
| Hegi, M | 1 |
| Cloughesy, T | 1 |
| Roth, P | 1 |
| Reardon, DA | 1 |
| Perry, JR | 1 |
| Mehta, MP | 1 |
| Stupp, R | 3 |
| Redjal, N | 1 |
| Reinshagen, C | 1 |
| Le, A | 1 |
| Walcott, BP | 1 |
| McDonnell, E | 1 |
| Dietrich, J | 1 |
| Nahed, BV | 1 |
| Ochiai, S | 1 |
| Nomoto, Y | 1 |
| Yamashita, Y | 1 |
| Watanabe, Y | 1 |
| Toyomasu, Y | 1 |
| Kawamura, T | 1 |
| Takada, A | 1 |
| Ii, N | 1 |
| Kobayashi, S | 1 |
| Sakuma, H | 1 |
| Proske, J | 1 |
| Walter, L | 1 |
| Bumes, E | 1 |
| Hutterer, M | 1 |
| Vollmann-Zwerenz, A | 1 |
| Eyüpoglu, IY | 1 |
| Savaskan, NE | 1 |
| Seliger, C | 1 |
| Hau, P | 2 |
| Uhl, M | 1 |
| Rudà, R | 1 |
| Pellerino, A | 1 |
| Soffietti, R | 1 |
| Fay, MF | 1 |
| Dowson, N | 1 |
| Rose, SE | 1 |
| Felix, F | 1 |
| Fontenele, J | 1 |
| Hoja, S | 1 |
| Schulze, M | 1 |
| Rehli, M | 1 |
| Proescholdt, M | 1 |
| Herold-Mende, C | 1 |
| Riemenschneider, MJ | 1 |
| Habets, JGV | 1 |
| Leentjens, AFG | 1 |
| Schijns, OEMG | 1 |
| Zhang, C | 1 |
| Liu, S | 1 |
| Yuan, X | 1 |
| Hu, Z | 1 |
| Li, H | 1 |
| Wu, M | 1 |
| Yuan, J | 1 |
| Zhao, Z | 1 |
| Su, J | 1 |
| Wang, X | 1 |
| Liao, Y | 1 |
| Liu, Q | 1 |
| Watanabe, S | 2 |
| Kuwabara, Y | 1 |
| Suehiro, S | 1 |
| Yamashita, D | 1 |
| Tanaka, M | 1 |
| Tanaka, A | 1 |
| Ohue, S | 1 |
| Araki, H | 1 |
| Tseng, JH | 1 |
| Chen, CY | 1 |
| Hsiao, SH | 1 |
| Fan, CC | 1 |
| Liang, YC | 1 |
| Chen, CP | 1 |
| Kim, B | 1 |
| Rincón Castro, LM | 1 |
| Jawed, S | 1 |
| Niles, LP | 1 |
| Wu, X | 1 |
| Chen, PS | 1 |
| Dallas, S | 1 |
| Wilson, B | 1 |
| Block, ML | 1 |
| Wang, CC | 1 |
| Kinyamu, H | 1 |
| Lu, N | 1 |
| Gao, X | 1 |
| Leng, Y | 1 |
| Chuang, DM | 1 |
| Zhang, W | 1 |
| Lu, RB | 1 |
| Hong, JS | 1 |
| Patel, A | 1 |
| Suzuki, M | 1 |
| Kurozumi, K | 1 |
| Saeki, Y | 1 |
| Wolff, JE | 3 |
| Kortmann, RD | 1 |
| Jorch, N | 1 |
| Gnekow, A | 1 |
| Driever, PH | 2 |
| Chinnaiyan, P | 1 |
| Cerna, D | 2 |
| Burgan, WE | 2 |
| Beam, K | 1 |
| Williams, ES | 1 |
| Psaras, T | 1 |
| Will, BE | 1 |
| Schoeber, W | 1 |
| Rona, S | 1 |
| Mittelbronn, M | 1 |
| Honegger, JB | 1 |
| Oi, S | 1 |
| Natsume, A | 1 |
| Ito, M | 1 |
| Kondo, Y | 1 |
| Shimato, S | 1 |
| Maeda, Y | 1 |
| Saito, K | 1 |
| Wakabayashi, T | 1 |
| Neyns, B | 1 |
| Hoorens, A | 1 |
| Rijsman, RM | 1 |
| Labro, H | 1 |
| Al-Kadhimi, Z | 1 |
| Djmil, M | 1 |
| Oghlakian, R | 1 |
| Alshekhlee, A | 1 |
| Fu, J | 1 |
| Shao, CJ | 1 |
| Chen, FR | 1 |
| Ng, HK | 1 |
| Chen, ZP | 1 |
| Papi, A | 1 |
| Ferreri, AM | 1 |
| Rocchi, P | 1 |
| Guerra, F | 1 |
| Orlandi, M | 1 |
| Chabbchoub Ben Abdallah, R | 1 |
| Kammoun, F | 1 |
| Ayedi, M | 1 |
| Trabelsi, L | 1 |
| Ben Salah, M | 1 |
| Ben Hlima, N | 1 |
| Mahfoudh, A | 1 |
| Manyam, SC | 1 |
| Kung, DH | 1 |
| Rhodes, LB | 1 |
| Newmark, ME | 1 |
| Friedman, DE | 1 |
| Golan, M | 1 |
| Schreiber, G | 1 |
| Avissar, S | 1 |
| Felix, FH | 2 |
| Trompieri, NM | 2 |
| de Araujo, OL | 2 |
| da Trindade, KM | 2 |
| Fontenele, JB | 2 |
| Cairncross, JG | 1 |
| Mason, W | 1 |
| Belanger, K | 1 |
| Brandes, AA | 1 |
| Bogdahn, U | 1 |
| Macdonald, DR | 1 |
| Forsyth, P | 1 |
| Rossetti, AO | 1 |
| Lacombe, D | 1 |
| Mirimanoff, RO | 1 |
| Van Nifterik, KA | 1 |
| Van den Berg, J | 1 |
| Slotman, BJ | 1 |
| Lafleur, MV | 1 |
| Stalpers, LJ | 1 |
| Poljakova, J | 2 |
| Hrebackova, J | 1 |
| Dvorakova, M | 1 |
| Moserova, M | 1 |
| Eckschlager, T | 2 |
| Hrabeta, J | 2 |
| Göttlicherova, M | 1 |
| Kopejtkova, B | 1 |
| Frei, E | 1 |
| Kizek, R | 1 |
| Stiborova, M | 2 |
| Tsai, HC | 1 |
| Wei, KC | 1 |
| Tsai, CN | 1 |
| Huang, YC | 1 |
| Chen, PY | 1 |
| Chen, SM | 1 |
| Lu, YJ | 1 |
| Lee, ST | 1 |
| Fisch, L | 1 |
| Mégevand, P | 1 |
| Badoud, S | 1 |
| Badoud, A | 1 |
| Seeck, M | 1 |
| Burkhard, PR | 1 |
| Osuka, S | 1 |
| Takano, S | 1 |
| Ishikawa, E | 1 |
| Yamamoto, T | 1 |
| Matsumura, A | 1 |
| Park, KY | 2 |
| Kim, SM | 2 |
| Jeong, CH | 2 |
| Woo, JS | 2 |
| Hou, Y | 2 |
| Chen, Y | 1 |
| Tsai, YH | 1 |
| Tseng, SH | 1 |
| Broekman, M | 1 |
| Snijders, T | 1 |
| van Es, C | 1 |
| de Vos, F | 1 |
| Regli, L | 1 |
| Robe, P | 1 |
| Yoon, WS | 1 |
| Lim, JY | 1 |
| Asklund, T | 1 |
| Kvarnbrink, S | 1 |
| Holmlund, C | 1 |
| Wibom, C | 1 |
| Bergenheim, T | 1 |
| Henriksson, R | 1 |
| Hedman, H | 1 |
| Guthrie, GD | 1 |
| Dinapoli, L | 1 |
| Sperati, F | 1 |
| Pace, A | 1 |
| Fabi, A | 1 |
| Vidiri, A | 1 |
| Pompili, A | 1 |
| Carapella, CM | 1 |
| White, MC | 1 |
| Frampton, AR | 1 |
| Groh, T | 1 |
| Sokolski, KN | 1 |
| Denson, TF | 1 |
| Scott, T | 1 |
| Sproull, M | 1 |
| Cerra, MA | 1 |
| Fine, H | 1 |
| Sirven, JI | 1 |
| Wingerchuk, DM | 1 |
| Drazkowski, JF | 1 |
| Lyons, MK | 1 |
| Zimmerman, RS | 1 |
| Wagner, S | 1 |
| Csatary, CM | 1 |
| Gosztonyi, G | 1 |
| Koch, HC | 1 |
| Hartmann, C | 1 |
| Peters, O | 1 |
| Hernáiz-Driever, P | 1 |
| Théallier-Janko, A | 1 |
| Zintl, F | 1 |
| Längler, A | 1 |
| Csatary, LK | 1 |
| Furchert, SE | 1 |
| Lanvers-Kaminsky, C | 1 |
| Juürgens, H | 1 |
| Jung, M | 1 |
| Loidl, A | 1 |
| Frühwald, MC | 1 |
| Grewal, J | 1 |
| Dellinger, CA | 1 |
| Yung, WK | 1 |
| Das, CM | 1 |
| Aguilera, D | 1 |
| Vasquez, H | 1 |
| Prasad, P | 1 |
| Zhang, M | 1 |
| Gopalakrishnan, V | 1 |
| Wang, AD | 1 |
| Ji, XY | 1 |
| Huang, Q | 1 |
| Wang, CR | 1 |
| Dong, J | 1 |
| Lan, Q | 1 |
| Landau, J | 1 |
| Baulac, M | 1 |
| Durand, G | 1 |
| de Billy, A | 1 |
| Philippon, J | 1 |
| Hennessy, MJ | 1 |
| Wiles, CM | 1 |
| Glantz, MJ | 1 |
| Cole, BF | 1 |
| Friedberg, MH | 1 |
| Lathi, E | 1 |
| Choy, H | 1 |
| Furie, K | 1 |
| Akerley, W | 1 |
| Wahlberg, L | 1 |
| Lekos, A | 1 |
| Louis, S | 1 |
| Chen, G | 1 |
| Manji, HK | 1 |
| Wright, CB | 1 |
| Hawver, DB | 1 |
| Potter, WZ | 1 |
| Lehmann, DF | 1 |
| Hurteau, TE | 1 |
| Newman, N | 1 |
| Coyle, TE | 1 |
| Cortés, V | 1 |
| Landete, L | 1 |
| Gómez, E | 1 |
| Blasco, R | 1 |
| Arroyo, S | 1 |
| Rumiá, J | 1 |
| Martínez, I | 1 |
| Ribalta, T | 1 |
| Wolfson, M | 1 |
| Bersudsky, Y | 1 |
| Zinger, E | 1 |
| Simkin, M | 1 |
| Belmaker, RH | 1 |
| Hertz, L | 1 |
| Proulle, V | 1 |
| Masnou, P | 1 |
| Cartron, J | 1 |
| Kaplan, C | 1 |
| Ajzenberg, N | 1 |
| Tchernia, G | 1 |
| Dreyfus, M | 1 |
| Bourg, V | 1 |
| Lebrun, C | 1 |
| Chichmanian, RM | 1 |
| Thomas, P | 1 |
| Frenay, M | 1 |
| Cinatl, J | 2 |
| Kotchetkov, R | 1 |
| Blaheta, R | 1 |
| Vogel, JU | 1 |
| Churchyard, A | 1 |
| Khangure, M | 1 |
| Grainger, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Prospective Trial for Validation of the Role of Levetiracetam as a Sensitizer of Temozolomide in the Treatment of Newly Diagnosed Glioblastoma Patients[NCT02815410] | Phase 2 | 73 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| An Open-label, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Doxorubicin in Combination With Radiotherapy, Temozolomide and Valproic Acid in Patients With Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG)[NCT02758366] | Phase 2 | 21 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to Study was terminated due to high heterogeneity of enrolled patients) | ||
| Valproic Acid for Children With Recurrent and Progressive Brain Tumors[NCT01861990] | Phase 1 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to Feasibility of the trial was proven to be absent.) | ||
| Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study[NCT00006353] | Phase 3 | 575 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for valproic acid and Brain Neoplasms
| Article | Year |
|---|---|
Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma.
Topics: Brain Neoplasms; Clinical Trials as Topic; Exportin 1 Protein; Glioblastoma; Humans; Karyopherins; N | 2021 |
Management of epilepsy in brain tumor patients.
Topics: Anticonvulsants; Benzodiazepines; Brain Neoplasms; Epilepsy; Humans; Isocitrate Dehydrogenase; Lacos | 2022 |
Epilepsy and brain tumors: Two sides of the same coin.
Topics: Anticonvulsants; Brain Neoplasms; Epilepsy; Humans; Levetiracetam; Valproic Acid | 2023 |
Valproate and lithium: Old drugs for new pharmacological approaches in brain tumors?
Topics: Antimanic Agents; Bipolar Disorder; Brain Neoplasms; Glioblastoma; Humans; Lithium; Lithium Carbonat | 2023 |
The therapeutic and neuroprotective effects of an antiepileptic drug valproic acid in glioma patients.
Topics: Anticonvulsants; Brain Neoplasms; Glioma; Humans; Neuroprotective Agents; Valproic Acid | 2020 |
SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.
Topics: Anticonvulsants; Brain Neoplasms; Humans; Postoperative Period; Seizures; Valproic Acid | 2021 |
The survival effect of valproic acid in glioblastoma and its current trend: a systematic review and meta-analysis.
Topics: Anticonvulsants; Brain Neoplasms; Cohort Studies; Glioblastoma; Humans; Retrospective Studies; Survi | 2018 |
Choice of therapeutic anti-seizure medication in patients with brain tumour.
Topics: Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Epilepsy; Gabapentin; Glioma; Humans; L | 2019 |
Valproate induced hyperammonemic encephalopathy successfully treated with levocarnitine.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Diagnosis, Differential; Humans; Hyperammonemia; Male; Neur | 2014 |
Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; Depsipeptides; Epigenesis, Genetic; Glioblastoma | 2014 |
Survival analysis for valproic acid use in adult glioblastoma multiforme: a meta-analysis of individual patient data and a systematic review.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Survival Analysis; Treatme | 2014 |
Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics.
Topics: Animals; Anticonvulsants; Brain Neoplasms; Carbamazepine; Humans; Levetiracetam; Piracetam; Seizures | 2016 |
Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence.
Topics: Anticonvulsants; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Radiation-Sensitizing Age | 2016 |
Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy | 2012 |
Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Brain Neoplasms; Carbamazepine; Cohort Studies; Female; Gl | 2013 |
Seizure prophylaxis in patients with brain tumors: a meta-analysis.
Topics: Anticonvulsants; Brain Neoplasms; Comorbidity; Confidence Intervals; Dose-Response Relationship, Dru | 2004 |
4 trials available for valproic acid and Brain Neoplasms
| Article | Year |
|---|---|
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Chemoradi | 2015 |
Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma.
Topics: Adolescent; Brain Neoplasms; Child; Child, Preschool; Enzyme Inhibitors; Female; Follow-Up Studies; | 2008 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors.
Topics: Anticonvulsants; Brain Neoplasms; Data Collection; Double-Blind Method; Female; Humans; Incidence; M | 1996 |
98 other studies available for valproic acid and Brain Neoplasms
| Article | Year |
|---|---|
Valproic Acid Inhibits Glioma and Its Mechanisms.
Topics: Brain Neoplasms; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Glioma; Humans; Valproic Acid | 2022 |
Administration of Valproic Acid Improves the Survival of Patients with Glioma Treated with Postoperative Radiotherapy.
Topics: Brain Neoplasms; Glioma; Humans; Kaplan-Meier Estimate; Prognosis; Retrospective Studies; Survival R | 2022 |
Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines.
Topics: Adult; Apoptosis; Biperiden; Brain Neoplasms; Cell Line, Tumor; Dextromethorphan; Fingolimod Hydroch | 2022 |
Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines.
Topics: Adult; Apoptosis; Biperiden; Brain Neoplasms; Cell Line, Tumor; Dextromethorphan; Fingolimod Hydroch | 2022 |
Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines.
Topics: Adult; Apoptosis; Biperiden; Brain Neoplasms; Cell Line, Tumor; Dextromethorphan; Fingolimod Hydroch | 2022 |
Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines.
Topics: Adult; Apoptosis; Biperiden; Brain Neoplasms; Cell Line, Tumor; Dextromethorphan; Fingolimod Hydroch | 2022 |
Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Case-Contr | 2020 |
Multinodular and vacuolating neuronal tumour of the cerebrum: an incidental diagnosis in a child presenting with absence seizures.
Topics: Anticonvulsants; Brain Neoplasms; Child; Diagnosis, Differential; Ganglioneuroma; Humans; Magnetic R | 2021 |
Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide: A nationwide population-based cohort study in Taiwan.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Enzyme Inhibitors; Fema | 2020 |
Valproic Acid Sensitizes Glioma Cells to Luteolin Through Induction of Apoptosis and Autophagy via Akt Signaling.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Glioma; Huma | 2021 |
Combination treatment with VPA and MSCs‑TRAIL could increase anti‑tumor effects against intracranial glioma.
Topics: Adenoviridae; Animals; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Ce | 2021 |
First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Female; Glioma; Humans; Levetiracetam; Male; Middle Aged; R | 2021 |
Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling.
Topics: Adolescent; Brain Neoplasms; Glioblastoma; Humans; Methylation; Prognosis; Temozolomide; Valproic Ac | 2022 |
Lacosamide Lowers Valproate and Levetiracetam Levels.
Topics: Acetamides; Adolescent; Anticonvulsants; Brain Neoplasms; Drug Interactions; Epilepsies, Partial; Hu | 2017 |
Sodium Valproate as a Continuous Subcutaneous Infusion: A Case Series.
Topics: Adult; Aged; Anticonvulsants; Brain Neoplasms; Humans; Infusions, Subcutaneous; Middle Aged; Seizure | 2017 |
Bone morphogenetic protein signaling mediated by ALK-2 and DLX2 regulates apoptosis in glioma-initiating cells.
Topics: Activin Receptors, Type I; Animals; Apoptosis; Bone Morphogenetic Proteins; Brain Neoplasms; Cell Di | 2017 |
Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell | 2018 |
Cellular Effects of the Antiepileptic Drug Valproic Acid in Glioblastoma.
Topics: Action Potentials; Anticonvulsants; Brain Neoplasms; Calcium; Calcium-Calmodulin-Dependent Protein K | 2017 |
Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response.
Topics: Amino Acid Transport System y+; Animals; Ascorbic Acid; Brain Neoplasms; Cell Death; Cell Line, Tumo | 2018 |
Valproate sensitizes human glioblastoma cells to 3-bromopyruvate-induced cytotoxicity.
Topics: Adenosine Triphosphate; Antineoplastic Agents; ATP-Binding Cassette Transporters; Brain Neoplasms; C | 2018 |
AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro.
Topics: Anticonvulsants; Antineoplastic Agents; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Pr | 2019 |
Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Gliob | 2019 |
Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
Topics: Amphiregulin; Antibodies, Blocking; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neop | 2019 |
Does the choice of antiepileptic drug have an impact on the survival of glioblastoma multiforme?
Topics: Antineoplastic Agents; Brain Neoplasms; Enzyme Inhibitors; Female; Glioblastoma; Humans; Male; Valpr | 2013 |
Valproic acid use during radiation therapy for glioblastoma associated with improved survival.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combin | 2013 |
Valproic acid and its inhibition of tumor growth in systemic malignancies: beyond gliomas.
Topics: Anticonvulsants; Apoptosis; Brain Neoplasms; Cell Movement; Glioma; Humans; Valproic Acid | 2013 |
Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2013 |
Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma?
Topics: Anticonvulsants; Brain Neoplasms; Female; Glioblastoma; Humans; Levetiracetam; Male; Neoplasm Recurr | 2013 |
Levetiracetam compared with valproic acid for the prevention of postoperative seizures after supratentorial tumor surgery: a retrospective chart review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Child; Child, Preschoo | 2013 |
STAT3 activation promotes oncolytic HSV1 replication in glioma cells.
Topics: Anticonvulsants; Blotting, Western; Brain Neoplasms; Cell Proliferation; Combined Modality Therapy; | 2013 |
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Topics: Animals; Anoikis; Antineoplastic Agents, Hormonal; Apoptosis Regulatory Proteins; bcl-2 Homologous A | 2013 |
Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Endopl | 2014 |
Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Dacarba | 2014 |
[Effect of capecitabine therapy on the blood levels of antiepileptic drugs - report of two cases].
Topics: Anticonvulsants; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Capecitabine; D | 2014 |
The effects of selected inhibitors of histone modifying enzyme on C6 glioma cells.
Topics: Acetylation; Adenosine; Animals; Azepines; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme | 2014 |
Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study.
Topics: Adult; Aged; Anticonvulsants; Blood Cell Count; Blood Cells; Brain Neoplasms; Chemoradiotherapy; Fem | 2015 |
Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy.
Topics: Anesthesia, General; Anesthesia, Local; Anticonvulsants; Aphasia; Benzodiazepines; Brain Diseases; B | 2015 |
[Clinical misdiagnosis analysis of valproate encephalopathy].
Topics: Anticonvulsants; Brain Diseases; Brain Edema; Brain Neoplasms; Diagnostic Errors; Epilepsy; Humans; | 2014 |
The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2015 |
SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Brain Neoplasm | 2015 |
Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cranial Irradiation; | 2015 |
Prognostic relevance of epilepsy at presentation in glioblastoma patients.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Epilepsy; Female; Glioblastoma; Humans; Immunohistochemistr | 2016 |
Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.
Topics: Acetylation; Acetyltransferases; Anilides; Brain Neoplasms; Capsid; Cell Line, Tumor; Cell Nucleus; | 2015 |
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2016 |
Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brai | 2016 |
Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma.
Topics: Adaptive Immunity; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplas | 2016 |
Does valproic acid affect tumor growth and improve survival in glioblastomas?
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Prol | 2016 |
Valproate in Adjuvant Glioblastoma Treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therap | 2016 |
Valproic Acid May Be Tested in Patients With H3F3A-Mutated High-Grade Gliomas.
Topics: Brain Neoplasms; Glioma; Humans; Mutation; Valproic Acid | 2016 |
Molecular dissection of the valproic acid effects on glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin; Dacarbazine; Decision Support Syst | 2016 |
Serious and reversible levetiracetam-induced psychiatric symptoms after resection of frontal low-grade glioma: two case histories.
Topics: Anticonvulsants; Brain Neoplasms; Craniotomy; Epilepsy; Frontal Lobe; Humans; Levetiracetam; Magneti | 2017 |
Valproic Acid Promotes Human Glioma U87 Cells Apoptosis and Inhibits Glycogen Synthase Kinase-3β Through ERK/Akt Signaling.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Enzyme Activation; Extracellular Signal-Regulated MAP | 2016 |
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2017 |
Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression.
Topics: Animals; Aryldialkylphosphatase; Bcl-2-Like Protein 11; Blotting, Western; Brain Neoplasms; Cell Lin | 2017 |
Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epi | 2008 |
Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons.
Topics: Animals; Astrocytes; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Cells, Cultured; Cerebral C | 2008 |
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Butyrates; Drug Synergism; Drug Therapy, Combinatio | 2008 |
Postradiation sensitization of the histone deacetylase inhibitor valproic acid.
Topics: Brain Neoplasms; Cell Line, Tumor; Enzyme Inhibitors; Glioma; Histone Deacetylase Inhibitors; Humans | 2008 |
Quantitative assessment of postoperative blood collection in brain tumor surgery under valproate medication.
Topics: Adult; Aged; Anticonvulsants; Blood Cell Count; Blood Chemical Analysis; Blood Volume; Brain Neoplas | 2008 |
Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells.
Topics: Antigens, Neoplasm; Azacitidine; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Decitabine; D | 2009 |
Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Chemothe | 2008 |
Efficacy of anti-epileptic drugs in patients with gliomas and seizures.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Carbamazepine; Drug Therapy, Combination; Female; Follow-Up | 2009 |
Brain amyloidoma with cerebral hemorrhage.
Topics: Amyloidosis; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhag | 2009 |
Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines.
Topics: Animals; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cel | 2010 |
Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells.
Topics: Anticonvulsants; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation | 2010 |
[Multiple cerebral cavernomatosis in a 1-year-old child].
Topics: Brain Neoplasms; Female; Hemangioma, Cavernous; Humans; Infant; Magnetic Resonance Imaging; Seizures | 2010 |
Unilateral opercular lesion and eating-induced seizures.
Topics: Anticonvulsants; Brain Neoplasms; Cerebral Cortex; Diagnosis, Differential; Eating; Electroencephalo | 2010 |
Antidepressants elevate GDNF expression and release from C₆ glioma cells in a β-arrestin1-dependent, CREB interactive pathway.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents | 2011 |
Potential role for valproate in the treatment of high--risk brain tumors of childhood-results from a retrospective observational cohort study.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Cohort Studies; Humans; | 2011 |
Valproic acid as the AED of choice for patients with glioblastoma? The jury is out.
Topics: Anticonvulsants; Brain Neoplasms; Glioblastoma; Humans; Seizures; Valproic Acid | 2011 |
Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine | 2012 |
Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; DNA Damage; Dose-Response | 2011 |
Effect of valproic acid on the outcome of glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; | 2012 |
Pilomotor seizure: when paroxysmal gooseflesh heralds brain tumor.
Topics: Aged; Amygdala; Anticonvulsants; Astrocytoma; Brain Neoplasms; Electroencephalography; Hippocampus; | 2012 |
Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain.
Topics: Angiogenesis Inhibitors; Animals; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Cell Line | 2012 |
Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Bystander Effect; Cell Line, Tumor; Connexins; Genetic Therapy; | 2012 |
Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms.
Topics: Anticonvulsants; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Movement; Flow Cytometry; Gliom | 2012 |
Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enz | 2012 |
Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasm | 2012 |
Survival of children with malignant brain tumors receiving valproate: a retrospective study.
Topics: Anticonvulsants; Brain Neoplasms; Child; Cohort Studies; Female; Follow-Up Studies; Humans; Kaplan-M | 2013 |
Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Benzodiazepines; Brain Neoplasms; Carbamazepine; Clobazam; Dr | 2012 |
The histone deacetylase inhibitor valproic acid enhances equine herpesvirus type 1 (EHV-1)-mediated oncolysis of human glioma cells.
Topics: Animals; Brain Neoplasms; Genetic Vectors; Glioma; Herpesvirus 1, Equid; Histone Deacetylase Inhibit | 2013 |
Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Marrow Neoplasms; Brain Neoplasms; Cell Cycle; Ce | 2012 |
Exacerbation of mania secondary to right temporal lobe astrocytoma in a bipolar patient previously stabilized on valproate.
Topics: Anticonvulsants; Antimanic Agents; Astrocytoma; Bipolar Disorder; Brain Neoplasms; Disease Progressi | 2003 |
Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid.
Topics: Acetylation; Animals; Brain Neoplasms; Cell Death; Cell Proliferation; Disease Progression; DNA Repa | 2005 |
Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid.
Topics: Administration, Oral; Anticonvulsants; Antigens, Viral; Astrocytoma; Brain; Brain Neoplasms; Child; | 2006 |
Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.
Topics: Acetylation; Annexin A5; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Enzyme Inh | 2007 |
Fatal reactivation of hepatitis B with temozolomide.
Topics: Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fatal Outcom | 2007 |
Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
[Studies on the target cells and molecules with sodium valproate induced differential of human glioma cells].
Topics: AC133 Antigen; Actins; Animals; Antigens, CD; Brain Neoplasms; Cell Differentiation; Flow Cytometry; | 2007 |
Impairment of consciousness induced by valproate treatment following neurosurgical operation.
Topics: Adolescent; Adult; Arousal; Brain Neoplasms; Cerebral Hemorrhage; Coma; Consciousness Disorders; Del | 1993 |
Lamotrigine encephalopathy.
Topics: Anticonvulsants; Astrocytoma; Brain Diseases; Brain Neoplasms; Drug Interactions; Female; Frontal Lo | 1996 |
Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells.
Topics: Adenylyl Cyclases; Animals; Brain Neoplasms; Glioma; GTP-Binding Proteins; Radioligand Assay; Rats; | 1996 |
Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors.
Topics: Adult; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain | 1997 |
[Partial simple vegetative crisis: importance of electroencephalographic findings].
Topics: Anticonvulsants; Astrocytoma; Brain Neoplasms; Electroencephalography; Epilepsies, Partial; Female; | 1997 |
[Drug-resistant epilepsy].
Topics: Adult; Anticonvulsants; Brain Neoplasms; Calcinosis; Carbamazepine; Diagnosis, Differential; Drug Re | 1998 |
Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations.
Topics: Antimanic Agents; Astrocytoma; Bipolar Disorder; Brain; Brain Neoplasms; Carbamazepine; Dose-Respons | 2000 |
GPIaIIa as a candidate target for anti-platelet autoantibody occurring during valproate therapy and associated with peroperative bleeding.
Topics: Adult; Anticonvulsants; Astrocytoma; Autoantibodies; Blood Platelets; Brain Neoplasms; Female; Hemor | 2000 |
Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispl | 2001 |
Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Cell Differentiation; Cell Division; DNA | 2002 |
Cerebral cavernous angioma: a potentially benign condition? Successful treatment in 16 cases.
Topics: Adolescent; Adult; Angiography; Brain Neoplasms; Carbamazepine; Cerebral Hemorrhage; Child; Epilepsy | 1992 |